Advocates press need for therapeutic solutions to address the addiction and mental health crises in the United States
DemeRx is studying the potential of noribogaine in supporting recovery for people with substance use disorders
January 10, 2025
In a recent episode of “The Joe Rogan Experience”, the discussion* centered on the pressing need for therapeutic solutions to address the addiction and mental health crises in the United States. Former Texas Governor Rick Perry and mental health advocate Brian Hubbard shared their insights and personal experience, drawing from their extensive backgrounds in public service. They emphasized the limitations of current medical treatments, particularly for individuals grappling with substance use disorders. The podcast poignantly addressed the profound impact addiction has on individuals, families, and society, while also focusing on the critical challenges faced by veterans returning from multiple combat tours.
Limitations of Current Treatments
This in-depth interview delved into the inadequacies of existing pharmaceutical treatments for addiction, post-traumatic stress disorder (PTSD), and brain trauma. Rogan emphasized the low success rates associated with abstinence-only programs. They emphasized the urgent need for more effective, evidence-based solutions. A significant portion of the podcast examined the potential of Ibogaine-based therapeutics in treating substance use disorders, citing a new study from Stanford University that demonstrates ibogaine’s neuro-regenerative effects and underscores the necessity for further research and clinical development (Nature Medicine volume 30, pages373–381 (2024) Link).
Noribogaine’s Therapeutic Potential
DemeRx, is advancing the development of noribogaine (DMX-1001), an active metabolite of ibogaine. We believe DMX-1001 is likely to retain the neuro-regenerative benefits of ibogaine that could aid patients with substance use disorders, while offering an improved safety profile compared to ibogaine. We are currently conducting a Phase 1 study in healthy volunteers to determine the pharmacokinetics, pharmacodynamics and safety of DMX-1001 for a potential Phase 2 trial in alcohol use disorder.
To gain deeper insights into the potential of DMX-1001 and its implications for treating addiction learn more about DemeRx at: https://www.demerx.com/the-science/
*Disclaimer: The views and opinions expressed in this podcast episode are those of the host and guests and do not necessarily reflect the views of DemeRx. While we find the topic relevant, we do not endorse all statements or perspectives shared in this discussion.